(Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the ...
The amount is the first post-trial win for AstraZeneca subsidiary Alexion but is a fraction of the indemnification the ...
AstraZeneca will move finance chief Marc Dunoyer to head newly acquired rare diseases business Alexion, using the $39 billion takeover as an opportunity to freshen up a management team that had been ...
Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile yesterday following the company’s agreement with Alexion, AstraZeneca Rare ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...
LONDON--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease has launched a new electronic storybook (e-book) to support children living with rare kidney disease, atypical Haemolytic Uraemic Syndrome ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pangaea Data, a company focused on detecting hard-to-diagnose diseases in patients, is partnering with Alexion, a subsidiary of AstraZeneca focused on treating rare diseases, to co-develop, clinically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results